Search

Your search keyword '"Hsing-Tao, K."' showing total 3 results
Start Over Author "Hsing-Tao, K."
3 results on '"Hsing-Tao, K."'

1. LBA2 Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): The RATIONALE-301 Chinese subpopulation analysis

Author

Qin, S., primary, Guo, Y., additional, Meng, Z., additional, Wu, J., additional, Gu, K., additional, Zhang, T., additional, Lin, X., additional, Lin, H., additional, Ying, J-E., additional, Zhou, F., additional, Hsing-Tao, K., additional, Chao, Y., additional, Li, S., additional, Chen, Y., additional, Boisserie, F., additional, Abdrashitov, R., additional, and Bai, Y., additional

Published
2022
Full Text
View/download PDF

2. LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Author

Qin, S., primary, Kudo, M., additional, Meyer, T., additional, Finn, R.S., additional, Vogel, A., additional, Bai, Y., additional, Guo, Y., additional, Meng, Z., additional, Zhang, T., additional, Satoh, T., additional, Hiraoka, A., additional, Marino, D., additional, Assenat, E., additional, Wyrwicz, L., additional, Campos, M. Calvo, additional, Hsing-Tao, K., additional, Boisserie, F., additional, Li, S., additional, Chen, Y., additional, and Zhu, A.X., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results